^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    α2 adrenergic receptor antagonist

    Related drugs:
    20d
    Effects of Mirtazapine on Appetite in Advanced Cancer Patients (clinicaltrials.gov)
    P2, N=98, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Dec 2027 --> Dec 2025
    Trial primary completion date
    22d
    A Study to Assess the Safety and Efficacy of Centhaquine in Hypovolemic Shock Patients (clinicaltrials.gov)
    P4, N=400, Recruiting, Pharmazz, Inc. | Trial completion date: Dec 2025 --> Aug 2026 | Trial primary completion date: Nov 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    23d
    A Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent (clinicaltrials.gov)
    P3, N=430, Not yet recruiting, Pharmazz, Inc. | Trial completion date: Oct 2026 --> Oct 2027
    Trial completion date
    27d
    Effects of Mirtazapine on Appetite in Advanced Cancer Patients (clinicaltrials.gov)
    P2, N=98, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    1m
    Novel Pilot Study to Treat Symptoms of IBS With Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodulator (clinicaltrials.gov)
    P1, N=20, Recruiting, Mayo Clinic | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    2ms
    O-GlcNAcylation of SPOP regulates colorectal cancer progression and ferroptosis by mediating β-catenin degradation. (PubMed, Cell Death Discov)
    Combined treatment with the SPOP-targeted drug maprotiline and a ferroptosis inducer has synergistic antitumor efficacy in CRC cells and xenografts. Our study reveals the multifaceted function of SPOP in CRC, and the activation of SPOP may be a feasible strategy to increase the sensitivity of CRC to ferroptosis inducers.
    Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1) • SPOP (Speckle Type BTB/POZ Protein) • SLC7A11 (Solute Carrier Family 7 Member 11)
    |
    maprotiline
    3ms
    Multicentric, Randomized Study to Assess Safety and Efficacy of Centhaquine in Patients With ARDS (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Pharmazz, Inc. | N=60 --> 80 | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
    Enrollment change • Trial completion date • Trial primary completion date
    4ms
    Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, University of California, Irvine | Trial completion date: Dec 2024 --> Dec 2030 | Trial primary completion date: Dec 2024 --> Dec 2030
    Trial completion date • Trial primary completion date
    |
    temozolomide
    5ms
    Reprogramming the Hepatic Immune Microenvironment with Mirtazapine in Early Neoplastic Transformation: Evidence from a Diethylnitrosamine-Induced Rat Model. (PubMed, Chem Biol Interact)
    Importantly, systems biology and network analysis confirmed these findings by demonstrating that mirtazapine modulates key immune-regulatory networks, particularly those governing T cell responses, cytokine signaling, and macrophage polarization, thus mechanistically validating its immunomodulatory and anti-tumor effects. These results highlight mirtazapine's potential for repurposing as a chemopreventive agent in inflammation-driven hepatic neoplasia.
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8) • CCND1 (Cyclin D1) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • MMP2 (Matrix metallopeptidase 2) • CASP3 (Caspase 3) • CD68 (CD68 Molecule) • TGFB1 (Transforming Growth Factor Beta 1) • IL17A (Interleukin 17A)
    6ms
    LYNX-2: Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances (clinicaltrials.gov)
    P3, N=200, Active, not recruiting, Ocuphire Pharma, Inc. | Trial primary completion date: Sep 2025 --> Apr 2025
    Trial primary completion date
    6ms
    An autopsy case of non-drug related progressive multifocal leukoencephalopathy in a background of rheumatoid arthritis (PubMed, Rinsho Shinkeigaku)
    Despite treatment with a combination of mefloquine and mirtazapine, the patient died on the 102nd day due to disease progression. RA with non-drug related immune abnormalities should be considered a potential underlying cause of PML.
    Journal
    |
    CD4 (CD4 Molecule)
    7ms
    A Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent (clinicaltrials.gov)
    P3, N=430, Not yet recruiting, Pharmazz, Inc. | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date